SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced data from a meta-analysis of overall survival in multiple myeloma (MM) patients receiving investigational maintenance ...
Patients who underwent Revlimid, Velcade, and dexamethasone therapy followed by maintenance Revlimid, tended to have better outcomes when they underwent autologous stem cell transplant. The addition ...
A dose-finding study presented at the recent American Society of Hematology annual meeting showed deep and durable responses with belantamab mafodotin (Blenrep) plus lenalidomide (Revlimid) and ...
Maintenance therapy with Ninlaro and Revlimid in patients with recently diagnosed multiple myeloma who underwent a stem cell transplant may safely improve survival, although more research is needed ...
BOSTON, June 6 (Reuters) - Two major studies of Celgene Corp's multiple myeloma drug Revlimid showed that when taken as maintenance therapy following stem-cell transplantation it reduced the risk of ...
Lupin has received approval from the Food and Drug Administration for lenalidomide capsules, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg, which are the generic of Bristol-Myers Squibb's Revlimid. The ...
The Food and Drug Administration has cleared Cipla’s lenalidomide capsules in dosage strengths of 5 mg, 10 mg, 15 mg and 25 mg. Cipla’s lenalidomide capsules are the generic of Bristol Myers Squibb’s ...
Summit, N.J., June 29 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has granted approval for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results